GlassScriptPhysician profile
Elizabeth T Lyons
NPI 1730474321
$6,259.01
in general payments reported to CMS, 2019-2025
28 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,991 · 2020: $1,808 · 2021: $1,912 · 2022: $365 · 2023: $20.15 · 2024: $63.16 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $183.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,354.31 | 2019-2024 | Enbrel, Otezla |
| Ucb, INC. | $642.85 | 2019-2025 | Bimzelx |
| Lilly USA, LLC | $608.39 | 2019-2024 | Taltz |
| Abbvie INC. | $588.66 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $525.80 | 2019-2022 | |
| Janssen Biotech, INC. | $355.54 | 2019-2022 | |
| Glaxosmithkline, LLC. | $339.41 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $246.91 | 2019-2021 | |
| Pfizer INC. | $205.45 | 2019-2022 | |
| Genentech USA, INC. | $160.70 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $151.73 | 2020-2021 | |
| Antares Pharma, INC. | $146.34 | 2019-2020 | |
| Horizon Therapeutics Plc | $139.99 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $114.45 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $109.28 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $87.38 | 2019-2021 | |
| Sobi, INC | $87.37 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.62 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $70.76 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $51.44 | 2021-2022 | |
| Radius Health, INC. | $47.85 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $44.30 | 2021 | |
| Gilead Sciences, INC. | $20.47 | 2020 | |
| Mallinckrodt Enterprises LLC | $19.87 | 2019 | |
| Biogen, INC. | $18.22 | 2019 | |
| Pacira Therapeutics, INC. | $14.28 | 2020 | |
| Merck Sharp & Dohme LLC | $14.24 | 2021 | |
| Organon LLC | $13.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.